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of calcein in 2008/MrP1 cells and moderately in 2008wt 
cells. a subsequent short (24 h) exposure to 2.3 μM l-leu-
covorin decreased calcein levels again in MrP1-over-
expressing cells. Folate deprivation markedly increased 
growth inhibitory effects of the established MrP1 sub-
strates daunorubicin (~twofold), doxorubicin (~fivefold), 
and methotrexate (~83-fold) in MrP1-overexpressing 
cells, proportional to MrP1 expression. In conclusion, 
this study demonstrates that increased cellular folate con-
centrations induce MrP1/aBCC1-related drug efflux and 
drug resistance. these results have important implications 
in the understanding of the role of MrP1 and its homologs 
in clinical drug resistance.
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Introduction
Folates are vitamins that are daily required for many bio-
synthetic processes. as one-carbon donors and cofactors, 
they play a role in the synthesis of amino acids (methio-
nine, serine), de novo purine synthesis, and synthesis of 
thymidylate for Dna synthesis [1]. In addition, folates 
influence gene expression via Dna methylation, as a 
result of methionine production from homocysteine and 
methyltetrahydrofolate.
Folate supplementation to the diet was earlier reported 
to protect against cancer and other diseases [2–4]. later, 
warnings were given that an abundant intake of folate 
might promote tumorigenesis of existing neoplasia [5, 6]. 
recently, however, meta-analyses indicated that folic acid 
supplementation does not affect incidence of site-specific 
cancer during the first years of folate treatment [7, 8].
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Folate supplementation has become an essential part 
of certain cancer chemotherapeutic regimens, since it 
reduces toxicity of antifolate-based treatments [9]. For 
instance, the folate leucovorin is commonly used to reduce 
antifolate toxicity in leukemias and several solid tumors 
[9, 10]. also, combination of the antifolate alimta (pem-
etrexed) with cisplatin was less toxic after folic acid sup-
plementation [11], and folic acid not only increased the 
efficacy of this combination, but also that of cisplatin as a 
single drug.
nowadays, there is growing evidence that dietary sup-
plements such as folic acid can mimic, intensify, or attenu-
ate the effects of chemotherapeutic agents [12].
One mechanism by which folates might influence chem-
otherapy is via their interaction with transporter proteins 
that cause multiple drug resistance (MDr). We earlier 
demonstrated, for instance, that folates enhance the cellular 
efflux of the anticancer agent daunorubicin (Dnr)-medi-
ated by the multidrug resistance protein 1 (MrP1/aBCC1) 
[13]. MrP1 is the founding member of the C-subclass of 
atP-binding cassette (aBC) transporters. Most of the 
nine MrP/aBCC members are lipophilic anion pumps 
that transport a range of structurally unrelated therapeutic 
drugs and other xenobiotics, as well as several physiologi-
cally important organic anions such as leukotriene C(4) 
and prostaglandin e2 out of the cell [14–22]. like other 
aBC transporters, such as P-glycoprotein (P-gp/aBCB1) 
and the breast cancer resistance protein (BCrP/aBCg2), 
expression of MrPs in cancer cells can confer resistance to 
a broad variety of anticancer agents. For detailed informa-
tion on MrP1 and its homologs, we refer to recent reviews 
[21, 22].
We and others reported that antifolates, including meth-
otrexate (MtX), are good substrates of most MrPs [20–
26]. these agents are structural analogs of natural reduced 
folates and act as antagonists of cellular folate metabolism. 
MtX is used in the treatment of several types of cancer 
and inflammatory diseases [1, 27]. Second generation anti-
folates such as raltitrexed (ZD1694) and alimta are regis-
tered for clinical use [28, 29].
In addition to MtX, also natural folates, such as folic 
acid and leucovorin, were identified as substrates of MrPs 
[24–26, 30]. accordingly, many MrPs play a role in anti-
folate resistance and in controlling cellular homeostasis of 
natural folates [30].
the above-mentioned observation that folates enhance 
the MrP1-mediated efflux of Dnr was ascribed to an 
induction of MrP1 transport activity, rather than to an 
increase in expression level of MrP1 [13]. this raised the 
question whether folate supplementation not only enhances 
MrP1 transport activity, but also induces MrP1-medi-
ated cellular drug resistance to Dnr and other anticancer 
agents.
In this study, we investigated whether folates provoke 
drug resistance to Dnr and structurally unrelated MrP1 
substrates. In addition, since Dnr is a positively charged 
agent, we now also studied whether folates induce cellular 
efflux of negatively charged compounds.
Materials and methods
reagents and cell lines
Folic acid, l-leucovorin (lV), verapamil (Vp), and digi-
tonin were obtained from Sigma Chemical Co. (St. louis, 
MO). Protease inhibitor cocktail was purchased from 
Boehringer, nl. normal rPMI-1640 medium (which con-
tains 2.3 μM folic acid), folate-free rPMI-1640 medium, 
normal fetal calf serum, and dialyzed fetal calf serum were 
obtained from gIBCO (grand Isl., nY). Daunorubicin 
HCl (Dnr) was from Specia (Paris, France). Doxoru-
bicin HCl (DOX) was obtained from Montedison neder-
land (rotterdam, the netherlands). MtX was a gift from 
Pharmachemie (Haarlem, the netherlands). Calcein-aM 
and the Dna probe Syto 13 were from Molecular Probes 
(eugene, Or). the MrP1 inhibitor MK571 (l-660,711) 
was obtained from Dr. robert Zamboni (Merck-Frost, 
Pointe-Claire, Quebec, Canada).
the human ovarian carcinoma cell line 2008wt, which 
expresses a basic level of MrP1, and its stable MrP1 
transfectant 2008/MrP1 were kindly provided by Prof. Dr. 
P. Borst (the netherlands Cancer Institute, amsterdam). 
these cell lines were cultured in rPMI 1640 medium, 
supplemented with 10 % FCS, 2 mM glutamine, and 
100 μg/ml penicillin/streptomycin. this culture medium 
is factory-supplied with 2.3 μM folic acid. For folate dep-
rivation, cells were cultured for 2 days in special folic 
acid-free rPMI 1640 medium supplemented with 10 % 
dialyzed FCS, 2 mM glutamine, and 100 μg/ml penicillin/
streptomycin.
growth inhibition
Cells (1 × 104–1.75 × 104/well) were seeded in 1 ml of cul-
ture medium in 24-well plates and cultured at 37 °C. Cells 
were allowed to attach for 24 h. Cells were then exposed 
to various concentrations of the drugs covering a three-log 
range for either 4 h (MtX) or 72 h (other drugs). Follow-
ing the 4-h exposure to MtX, the medium was aspirated, 
and the cells were washed thrice with 2.5 ml drug-free 
medium at 37 °C. thereafter, the cells were cultured for an 
additional 68 h at 37 °C. after 72 h, cells were detached by 
trypsinization, and the cells were counted using a micro-
cell counter. Finally, drug concentrations inhibiting 50 % 
growth inhibition (IC50) were determined.
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Cellular calcein accumulation
Steady-state cellular accumulation of calcein was meas-
ured using a method described by Feller et al. [31] with 
several modifications. Cells were plated in a 96-wells plate 
at a density of 2000 cells/well, 1 day prior to the measure-
ment. Cells were either cultured in folate-free or folate-rich 
medium (2.3 μM folic acid). the next day, all cells were 
exposed to 10 μM calcein-aM for 30 min. thereafter, 
fluorescence of the formed calcein was measured in a fluo-
rescence meter, type SpectraFluor (tecan austria gmbh, 
groedig, austria). the maximal level of calcein accumula-
tion was determined in control cells by adding 100 μM of 
the MrP1 inhibitor MK-571 [32] 10 min prior to the cal-
cein-aM exposure.
Cellular drug efflux
efflux of fluorescent calcein was measured using an online 
computerized method described by Wielinga et al. [33]. In 
brief, cells were cultured on glass coverslips that fitted to 
the wall of a cuvette of 1 × 1 × 4 cm (width, depth, and 
height). to load the cells with substrate, the coverslips were 
placed in a petri dish containing culture medium (37 °C), 
1 μM calcein-aM, and 150 μM Verapamil (to block 
MrP1-mediated efflux during the loading period) until 
steady state was reached (≥2 h). after loading, the cells 
were put on ice until further use.
For an efflux experiment, a coverslip was washed twice 
with ice-cold medium a (rPMI medium without phenol 
red). the coverslip was placed in the cuvette that con-
tained 3-ml warm (37 °C) medium a. the fluorescence of 
the effluxed substrate appearing in the medium was moni-
tored with a spectrafluorometer (FluoroMax, SPeX Indus-
tries, edison, nJ). Fluorescence of calcein was measured 
every second at excitations and emission wavelengths of 
492 and 530 nm, respectively. at the end of the experiment, 
25 μM digitonin was added to permeabilize the cells and 
to determine the total amount of intracellular Dnr. next, 
the cell number was determined by adding 400 nM of the 
Dna probe Syto 13. the Dnr signals were normalized for 
the Syto 13 signals. the fluorescence of Syto 13 was deter-
mined at excitation wavelength of 485 nm and emission 
wavelength of 520 nm.
nucleotide levels
extraction of nucleotides from cells was performed as 
described previously [34]. Subsequently, separation and 
quantification of the nucleotide pools were done using a 
gradient HPlC system consisting of two gyncotek pumps 
(model 300, Separation analytical Instruments BV, Hen-
drik Ido ambacht, the netherlands), as described earlier 
[34]. the HPlC system was connected to a photo-diode 
array detector (Separations, model 1000S), regularly set at 
254 and 280 nm. Chromatography peaks were quantitated 
using the data acquisition program Chromeleon 3.02.
Results
Folate-rich cell culture conditions are associated 
with increased MrP1 transport activity and a decreased 
cellular accumulation of calcein proportional to MrP1 
expression
In order to demonstrate that MrP1-mediated transport is 
controlled by the cellular folate status, we measured the cel-
lular extrusion of the model MrP1 substrate calcein [31] in 
cells with a basic level of MrP1 expression (2008wt cells) 
and in MrP1-overexpressing cells (2008/MrP1 cells). 
Both cell lines were cultured either continuously in stand-
ard rPMI medium containing 2.3 μM folic acid (folate-
rich), or for 48 h in folate-free medium. In folate-rich 
medium, the initial calcein efflux rate from 2008/MrP1 
cells was up to fourfold faster compared with the efflux 
from 2008wt cells (Fig. 1). after folate depletion for 48 h, 
the calcein efflux rate was about twofold decreased in the 
MrP1-transfected cells compared with folate-rich condi-
tions. also in the wild type cells, a significant reduction in 
calcein efflux (albeit smaller) could be observed.
We also examined the influence of cellular folate con-
centration on the steady-state accumulation of calcein in 
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Fig. 1  MrP1-mediated efflux of calcein. representative calcein 
efflux traces are shown for 2008wt cells and 2008/MrP1 cells. 
Cells were loaded with 1 μM calcein-aM for 1 h in the presence of 
150 μM verapamil (to block MrP1 and non-MrP-mediated extru-
sion during the loading period) prior to the efflux experiment. Prior 
to the experiment cells were cultured for 48 h in either folate-free 
medium (lF, low-folate), or folate-rich medium (HF, high folate). 
the fluorescent signals are plotted after normalization with respect 
to the total amount of Dnr in each experiment. SD between experi-
ments (n = 3) was <15 %
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MrP1 expressing cells. In standard folate-rich culture 
medium, the cellular accumulation of calcein in MrP1-
overexpressing 2008/MrP1 cells was 23 % of the cal-
cein level in their wild type counterparts 2008wt (Fig. 2). 
exposure to the MrP1 inhibitor MK571 completely 
equalized calcein accumulation between these two cell 
lines.
When cultured in folate-free medium for up to 10 days, 
the accumulation of calcein in 2008/MrP1 cells gradually 
increased fivefold (Fig. 3a). although less, even in 2008wt 
cells, a significant increase in calcein accumulation could 
be observed after folate depletion (Fig. 3b).
In Fig. 4, the effect on cellular calcein accumulation of 
a 24-h exposure to l-leucovorin after a folate-free period is 
shown. In the MrP1-overexpressing cells, this short-term 
l-leucovorin supplementation resulted in a restored calcein 
level that was comparable to levels found in continuous 
folate-rich conditions (Fig. 4).
Cellular nucleotide levels
Because the MrP1-mediated efflux of its substrates is 
energy-dependent, we verified whether cellular atP lev-
els remained sufficient during folate-free culture con-
ditions. During the first 7 days of folate depletion, no 
significant decrease in atP or other nucleotides was 
observed. Over a 10 days culture period in folate-free 
medium, atP levels gradually decreased to about half 
of those in both 2008wt and 2008/MrP1 cells (data not 
shown).
Increased folate concentration enhances MrP1-mediated 
drug resistance
as shown above, the cellular folate concentration is a deter-
mining factor in the transport activity of MrP1. It might 
therefore impact MrP1-mediated MDr. In order to study 
this, we performed growth inhibition experiments under 
different cellular folate conditions using the anthracyclines 
Dnr, and DOX, as well as MtX, vincristine and etopo-
side. all these agents are established MrP1 substrates. the 
IC50 values for these drugs were determined in 2008wt and 
2008/MrP1 cells that were cultured in either folic acid-
free medium or in folate-rich medium for 3 days. to pre-
vent polyglutamylation of MtX, which promotes cellular 
retention, exposure time for this drug was 4 h, followed by 
3-day drug-free culture.
Under folate-rich conditions, the 2008/MrP1 cells were 
highly resistant against all drugs compared with the 2008wt 
cells (Fig. 5). resistance factors were 5.8-fold (DOX), 
3.8-fold (Dnr), and 21.0-fold (MtX). When cultured in 
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Fig. 2  Cellular accumulation of calcein in MrP1-overexpressing 
cells. Steady-state accumulation of calcein in 2008wt cells (indi-
cated as Wt) and 2008/MrP1 cells (indicated as MrP1) is shown. 
Cells were cultured in standard, folate-rich medium. to determine 
the maximal reachable calcein level, cells were exposed to the MrP1 
inhibitor MK571 for 10 min prior to the loading of calcein (indicated 
with + in the figure). Fluorescent signals are given as Mean ± SD 
(n = 3). Asterisk indicates a significant difference compared with the 
maximal reachable calcein level in the same cell line (p < 0.05)
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Fig. 3  Influence of folate depletion in time on cellular accumula-
tion of calcein. Cells were cultured for 0–10 days in either folate-rich 
medium (white dots) or folate-free medium (black squares). at days 
3, 5, 7, and 10, cellular calcein accumulation was measured as in 
Fig. 2. a the influence of folate concentration in 2008/MrP1 cells, 
and b in 2008wt cells. Fluorescent signals are given as Mean ± SD 
(n = 4). Asterisk indicates a significant difference compared with 
folate-rich conditions (P < 0.05)
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folate-free medium, however, the IC50 values for DOX 
and MtX were markedly lower in the MrP1-overexpress-
ing cells (fivefold, and 83-fold, respectively). For Dnr, a 
smaller but significant decrease was observed. For vincris-
tine and etoposide, however, toxicity was hardly affected 
by folate condition in 2008wt and 2008/MrP1 cells (data 
not shown).
Discussion
Folate supplementation is part of in several routine chem-
otherapy protocols to reduce drug toxicity [9, 10]. It also 
was reported as a strategy to increase antitumor activity 
[11, 12].
In recent years, it became clear that folates also inter-
act with aBC transporter proteins that play a role in MDr. 
Folic acid and leucovorin are, for instance, substrates of 
MrP1 and its homologs [24–26, 30]. However, the fact 
that many MDr pumps harbor the capacity to transport 
folates does not automatically imply that folates act as 
competitive inhibitors in MDr. We demonstrated in an 
earlier study that high cellular folate concentrations induce 
MrP1-mediated cellular efflux of the positively charged 
drug Dnr [13]. notably, two-day culture in folate-free 
medium decreased the total cellular Dnr efflux to 43 % in 
2008/MrP1 cells and to 84 % in 2008wt cells. repletion of 
folate by a 2–24-h exposure completely restored of Dnr 
efflux in these cells. Based on these observations, we then 
postulated that folates apparently interact with MrP1 in a 
similar way as gluthathione (gSH) [35].
gSH is crucial for MrP1-mediated transport of posi-
tively charged compounds like Dnr and DOX. Several 
studies debated on the exact role of gSH in MrP1 activ-
ity [36, 37]. gSH was described as a co-substrate in trans-
port of positively charged drugs [36] and/or to form a con-
jugate with positively charged drugs [37]. Similarly, gSH 
and its non-reducing alkyl derivative S-methyl gSH were 
shown to stimulate MrP1 transport activity of endogenous 
compounds, rather than act as co-substrates or conjugates 
[38]. as proposed by Borst et al. [39], the glutamate resi-
due of gSH could be important in the binding to a reactive 
site in the MrP1 protein. like gSH, also folates contain 
0
10
20
30
40
50
60
70
80
90
100
2008wt 2008/MRP1
%
 c
al
ce
in
 a
cc
u
m
u
la
tio
n
*
*
Fig. 4  effect of l-leucovorin supplementation of cellular accu-
mulation of calcein in MrP1-overexpressing cells. accumulation 
of 1 μM calcein in 2008wt cells and 2008/MrP1 cells was deter-
mined as in Figs. 2 and 3. Cells were cultured for 7 days in folate-
rich medium (white bars), in folate-free medium (black bars), or in 
folate-free medium followed by a 24-h exposure to 2.3 μM l-leuco-
vorin (hatched bars). Fluorescent signals are given as Mean ± SeM 
(n = 3). Asterisk indicates a significant difference compared with 
folate-rich conditions in the same cell line (P < 0.05)
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Fig. 5  Influence of folate concentration on MrP1-associated drug 
resistance. growth inhibition by doxorubicin (DOX), daunorubicin 
(Dnr), and methotrexate (MtX) was determined in 2008wt cells and 
2008/MrP1 cells. IC50s for each drug were determined for a 3-day 
culture in either folate-rich medium (white bars), or in folate-free 
medium (black bars). During this period, drugs were continuously 
present, except for MtX. the latter was present during the first 4 h 
and subsequently washed away in order to prevent polyglutamylation 
of MtX. IC50s are given as Mean ± SD (n = 5)
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a glutamate residue that might play a key role in its inter-
action with MrPs. In this present study, we showed that 
basal efflux of the negatively charged compound calcein by 
MrP1 is enhanced by folates. Calcein is not dependent on 
gSH for its transport by MrP1 [31]. although this contra-
dicts an exact identical role for folates and gSH in MrP1 
activity, it does support the postulation that MrP1 activity 
is subject to various modes of modulation.
Other mechanisms through which folates might influ-
ence MrP1 transport activity are open for consideration. a 
decrease in cellular atP levels as a result of altered cellular 
folate status was excluded in our study as a possible cause of 
decreased MrP1 activity. Increments of cellular homocyst-
eine levels as a result of lowered folate status were reported 
[35], but whether these influence MrP1 function is not 
clear. Finally, the cellular folate status can influence indi-
rectly the regulation of gene expression through methylation 
of Cpg islands in the promoter region of a variety of genes 
[40, 41]. However, as we reported earlier, short folate deple-
tion periods (<10 days) did not impact the expression level 
of MrP1 protein [13]. reports of loss of MrP1 expression 
upon prolonged (>3 months) folate deprivation [42] were 
probably due to a selection process, in which a decreased 
MrP1 expression is physiologically beneficial to withhold 
intracellular folates under folate-restricted conditions.
an important issue is whether our “proof-of-principle” 
experiments in this study can be translated to MDr phe-
nomena in patients. First, folate levels in human plasma, 
in normal human tissues, and in solid tumors normally 
vary between 5 and 20 nM 5-methyltetrahydrofolate [12, 
43, 44]. these are approximately mimicked in the folate-
deprived cells in vitro. In contrast, the “folate-rich” con-
centrations used in our study were supraphysiological and 
would only represent cases of extreme folate oversupple-
mentation. Secondly, in the present study, we focused pri-
marily on MrP1. Conceivably, however, in MDr, a much 
broader range of MrP1 homologs as well as other aBC 
transporter proteins may contribute, including BCrP and 
Pgp. the dynamic interplay between all of these transport-
ers in a diversity of tissues and cell types has to be taken 
into account to fully understand the complete role of folates 
in MDr. expanding this study to other aBC transporters 
and clinically relevant physiological folate supplementation 
levels would merit further exploration.
In conclusion, folate supplementation during chemo-
therapy may have several impacts: reduction in toxicity, 
increase in antitumor activity, but also induction of MrP1 
transport activity and cellular drug resistance. these latter 
effects of folate intake and folate levels during chemother-
apy deserve ongoing considerations.
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